Company
Entrada Therapeutics, Inc. (TRDA)
Standardized SEC financial data for Entrada Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001689375 · NASDAQ · Pharmaceutical Preparations.
Operating margin
-621.1%
Net margin
-565.5%
Revenue growth (YoY)
-87.9%
Return on equity
-47.0%
Free cash flow
-$129.6M
Current ratio
12.53×
EPS (diluted)
$-3.47
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $129.0M | $210.8M | $25.4M |
| R&D expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $39.0M | $291.1M | $188.7M | $352.0M | $420.0M | $295.7M |
| Total current assets |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$25.6M | -$50.9M | -$93.8M | $139.8M | -$41.6M | -$128.5M |
| Capital expenditures |
Get TRDA data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/TRDA/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/TRDA/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"